675 Safety and tolerability of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma (RM-HNSCC)
A. Dimitrios Colevas(Cancer Institute (WIA)), Douglas Adkins(Washington University in St. Louis), John Park(California Baptist University), Venessa Chin(Garvan Institute of Medical Research), Katie Kerrigan(University of Utah), Lanjia Lin(Gilead Sciences (United States)), Michael F. Howland(Massachusetts Institute of Technology), Bruno Fang, José Dinis(Instituto Português de Oncologia Francisco Gentil), Diogo Alpuim Costa(Hospital do Desterro), Natalie Rainey(Queensland Government), Yiran Zhang(Jinan University), Siu-Chi Chang Sun(Gilead Sciences (United States)), Kelly K. Curtis(Gilead Sciences (United States)), Minh Phan(University of Oklahoma Health Sciences Center)
Cited by 1
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k